{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:58:01Z","timestamp":1779321481610,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":284,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.semnephrol.2023.151429","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T08:52:41Z","timestamp":1697878361000},"page":"151429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mustafa","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2023.151429_bib0001","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2020.08.017","article-title":"Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients","volume":"9","author":"Srivastava","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacbts.2021.10.018","article-title":"Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?","volume":"7","author":"Sharma","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0005","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0006","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0007","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0008","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0009","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198006193022501","article-title":"Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure","volume":"302","author":"Dzau","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0011","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0013","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ihj.2020.09.016","article-title":"Efficacy and safety of sacubitril\/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF India sub-study","volume":"72","author":"Jain","year":"2020","journal-title":"Indian Heart J"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0014","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jcpt.13243","article-title":"Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: a meta-analysis of randomized controlled trials","volume":"45","author":"Feng","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0018","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004356","article-title":"Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases","volume":"11","author":"Neumann","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/HYPERTENSIONAHA.117.09378","article-title":"Long-standing problem of beta-blocker-elicited hypoglycemia in diabetes mellitus","volume":"70","author":"Casiglia","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0022","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0889-8529(05)70164-X","article-title":"Dangerous and common drug interactions in patients with diabetes mellitus","volume":"29","author":"White","year":"2000","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0023","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0024","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0026","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cardfail.2022.05.014","article-title":"Can we stop reflexively discontinuing mineralocorticoid antagonists for patients with heart failure and hyperkalemia?","volume":"28","author":"Mastoris","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0027","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0028","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11892-020-01347-3","article-title":"What makes sodium-glucose co-transporter-2 inhibitors stand out in heart failure?","volume":"20","author":"Khan","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0032","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0033","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.hfc.2014.07.001","article-title":"Current perspectives on hydralazine and nitrate therapies in heart failure","volume":"10","author":"Cole","year":"2014","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0034","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ejhf.1474","article-title":"Novel potassium binders as enabling therapy in heart failure","volume":"21","author":"Butler","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0035","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0036","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/qjmed\/hcx118","article-title":"Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease","volume":"110","author":"Cheungpasitporn","year":"2017","journal-title":"QJM"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0037","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ejhf.2386","article-title":"Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0038","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0039","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jacc.2021.02.006","article-title":"Quadruple medical therapy for heart failure: medications working together to provide the best care","volume":"77","author":"Greene","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0041","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1159\/000524889","article-title":"Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV Trial","volume":"53","author":"Cherney","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0042","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0043","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15420\/cfr.2015.1.2.90","article-title":"Fluid management in patients with chronic heart failure","volume":"1","author":"Pellicori","year":"2015","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0044","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0045","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0046","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ehf2.12643","article-title":"Comparison of creatinine-based methods for estimating glomerular filtration rate in patients with heart failure","volume":"7","author":"Jonsson","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.semnephrol.2023.151429_bib0047","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.7326\/M22-0610","article-title":"Quantifying individual-level inaccuracy in glomerular filtration rate estimation: a cross-sectional study","volume":"175","author":"Shafi","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:50:05Z","timestamp":1748357405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0270929523001390"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151429","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151429"}}